This work is licensed under a Creative Commons Attribution 4.0 International License.
Tat-a5
General Information
DRACP ID DRACP00199
Peptide Name Tat-a5
Sequence KAQIRAMECNILGRKKRRQRRR
Sequence Length 22
UniProt ID Not available
PubChem CID Not available
Origin HIV-Tat (49-57)
Type Synthetic peptide
Classification
Active ACP Cancer targeted peptides
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| HCT 116 | Colon carcinoma | Carcinoma | ~80% Cytotoxicity at 100 µM | MTT assay | 24 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target HIV-Tat
Affinity Not available
Mechanism Tat-a5 could arrest cancer cells at G2/M phase and make them apoptotic; Tat-a5 would have the potential to inhibit tumor angiogenesis
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C113H211N49O28S2
Absent amino acids DFHPSTVWY
Common amino acids R
Mass 314310
Pl 12.64
Basic residues 10
Acidic residues 1
Hydrophobic residues 5
Net charge 9
Boman Index -12267
Hydrophobicity -167.27
Aliphatic Index 62.27
Half Life
Mammalian: 1.3 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 18656352
Title A novel peptide from alpha5 helix of Asterina pectinifera cyclin B conjugated to HIV-Tat(49-59) with cytotoxic and apoptotic effects against human cancer cells
Doi 10.1016/j.bmcl.2008.07.017
Year 2008
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.